97 related articles for article (PubMed ID: 26123090)
1. Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma.
van Dijk EH; van Herpen CM; Marinkovic M; Haanen JB; Amundson D; Luyten GP; Jager MJ; Kapiteijn EH; Keunen JE; Adamus G; Boon CJ
Ophthalmology; 2015 Sep; 122(9):1907-16. PubMed ID: 26123090
[TBL] [Abstract][Full Text] [Related]
2. Clinical and Morphologic Characteristics of Extracellular Signal-Regulated Kinase Inhibitor-Associated Retinopathy.
Francis JH; Canestraro J; Haggag-Lindgren D; Harding JJ; Diamond EL; Drilon A; Li BT; Iyer G; Schram AM; Abramson DH
Ophthalmol Retina; 2021 Dec; 5(12):1187-1195. PubMed ID: 34102344
[TBL] [Abstract][Full Text] [Related]
3. Morphological and Functional Correlations in Acute Central Serous Chorioretinopathy.
Kiraly P; Šuštar Habjan M; Smrekar J; Jaki Mekjavić P
Doc Ophthalmol; 2024 Jun; 148(3):145-153. PubMed ID: 38498077
[TBL] [Abstract][Full Text] [Related]
4. Paraneoplastic vitelliform retinopathy: clinicopathologic correlation and review of the literature.
Aronow ME; Adamus G; Abu-Asab M; Wang Y; Chan CC; Zakov ZN; Singh AD
Surv Ophthalmol; 2012 Nov; 57(6):558-64. PubMed ID: 22784677
[TBL] [Abstract][Full Text] [Related]
5. A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma.
Sacco JJ; Jackson R; Corrie P; Danson S; Evans TRJ; Ochsenreither S; Kumar S; Goodman A; Larkin J; Karydis I; Steven N; Lorigan P; Plummer R; Patel P; Psarelli E; Olsson-Brown A; Shaw H; Leyvraz S; Handley L; Rawcliffe C; Nathan P
Eur J Cancer; 2024 May; 202():114009. PubMed ID: 38547774
[TBL] [Abstract][Full Text] [Related]
6. Rapid diurnal variation of serous retinal detachment during BRAF and MEK inhibitor treatment: A case series.
Bravetti GE; Muggler K; Ben Aissa A; Thumann G; Malclès A
Acta Ophthalmol; 2024 Jun; 102(4):e651-e656. PubMed ID: 38235944
[No Abstract] [Full Text] [Related]
7. Globe Salvage and Vision Preservation by Neoadjuvant Darovasertib and Crizotinib in Uveal Melanoma.
Hiong A; O'Day R; Fog LS; McKay D; McKenzie J; Ameratunga M; Joshua AM; Shackleton M
Ophthalmol Retina; 2024 Apr; 8(4):325-330. PubMed ID: 37852320
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy.
Booth AEC; Hopkins AM; Rowland A; Kichenadasse G; Smith JR; Sorich MJ
Ther Adv Med Oncol; 2020; 12():1758835920944359. PubMed ID: 32821295
[TBL] [Abstract][Full Text] [Related]
9. Ocular Effects of MEK Inhibitor Therapy: Literature Review, Clinical Presentation, and Best Practices for Mitigation.
Jeng-Miller KW; Miller MA; Heier JS
Oncologist; 2024 May; 29(5):e616-e621. PubMed ID: 38527005
[TBL] [Abstract][Full Text] [Related]
10. A proposal for an updated staging system for LCHADD retinopathy.
Wongchaisuwat N; Gillingham MB; Yang P; Everett L; Gregor A; Harding CO; Sahel JA; Nischal KK; Scanga HL; Black D; Vockley J; Arnold G; Pennesi ME
Ophthalmic Genet; 2024 Apr; 45(2):140-146. PubMed ID: 38288966
[TBL] [Abstract][Full Text] [Related]
11. Multicentre analysis of nucleic acid quantification using aqueous humour liquid biopsy in uveal melanoma: implications for clinical testing.
Pike SB; Reid MW; Peng CC; Chang C; Xu BY; Gombos DS; Patel S; Xu L; Berry JL
Can J Ophthalmol; 2023 Nov; ():. PubMed ID: 38036045
[TBL] [Abstract][Full Text] [Related]
12. Clinical Performance and Management Outcomes with the DecisionDx-UM Gene Expression Profile Test in a Prospective Multicenter Study.
Plasseraud KM; Cook RW; Tsai T; Shildkrot Y; Middlebrook B; Maetzold D; Wilkinson J; Stone J; Johnson C; Oelschlager K; Aaberg TM
J Oncol; 2016; 2016():5325762. PubMed ID: 27446211
[TBL] [Abstract][Full Text] [Related]
13. Acute visual loss induced by dexamethasone during neoadjuvant docetaxol.
Gregory DL; Jones CD; Denton ER; Harnett AN
Clin Med Oncol; 2008; 2():37-42. PubMed ID: 21892264
[TBL] [Abstract][Full Text] [Related]
14. MEK inhibitor-associated retinopathy (MEKAR) in metastatic melanoma: Long-term ophthalmic effects.
Urner-Bloch U; Urner M; Jaberg-Bentele N; Frauchiger AL; Dummer R; Goldinger SM
Eur J Cancer; 2016 Sep; 65():130-8. PubMed ID: 27497344
[TBL] [Abstract][Full Text] [Related]
15. Ocular Toxicity in Metastatic Melanoma Patients Treated With Mitogen-Activated Protein Kinase Kinase Inhibitors: A Case Series.
Niro A; Strippoli S; Alessio G; Sborgia L; Recchimurzo N; Guida M
Am J Ophthalmol; 2015 Nov; 160(5):959-967.e1. PubMed ID: 26231307
[TBL] [Abstract][Full Text] [Related]
16. Subretinal Fluid Associated With MEK Inhibitor Use in the Treatment of Systemic Cancer.
Weber ML; Liang MC; Flaherty KT; Heier JS
JAMA Ophthalmol; 2016 Aug; 134(8):855-62. PubMed ID: 27309887
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy.
Francis JH; Habib LA; Abramson DH; Yannuzzi LA; Heinemann M; Gounder MM; Grisham RN; Postow MA; Shoushtari AN; Chi P; Segal NH; Yaeger R; Ho AL; Chapman PB; Catalanotti F
Ophthalmology; 2017 Dec; 124(12):1788-1798. PubMed ID: 28709702
[TBL] [Abstract][Full Text] [Related]
18. OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS.
Méndez-Martínez S; Calvo P; Ruiz-Moreno O; Pardiñas Barón N; Leciñena Bueno J; Gil Ruiz MDR; Pablo L
Retina; 2019 Aug; 39(8):1435-1450. PubMed ID: 30681641
[TBL] [Abstract][Full Text] [Related]
19. New features in MEK retinopathy.
Tyagi P; Santiago C
BMC Ophthalmol; 2018 Sep; 18(Suppl 1):221. PubMed ID: 30255823
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
